359 related articles for article (PubMed ID: 21053930)
1. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.
Shimada T; Tanaka K; Takenaka S; Murayama N; Martin MV; Foroozesh MK; Yamazaki H; Guengerich FP; Komori M
Chem Res Toxicol; 2010 Dec; 23(12):1921-35. PubMed ID: 21053930
[TBL] [Abstract][Full Text] [Related]
2. Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.
Shimada T; Murayama N; Tanaka K; Takenaka S; Guengerich FP; Yamazaki H; Komori M
Chem Res Toxicol; 2011 Aug; 24(8):1327-37. PubMed ID: 21732699
[TBL] [Abstract][Full Text] [Related]
3. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study.
Shimada T; Tanaka K; Takenaka S; Foroozesh MK; Murayama N; Yamazaki H; Guengerich FP; Komori M
Chem Res Toxicol; 2009 Jul; 22(7):1325-33. PubMed ID: 19563207
[TBL] [Abstract][Full Text] [Related]
4. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors.
Shimada T; Murayama N; Okada K; Funae Y; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2007 Mar; 20(3):489-96. PubMed ID: 17291012
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
Shimada T; Guengerich FP
Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
[TBL] [Abstract][Full Text] [Related]
6. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2.
Sridhar J; Ellis J; Dupart P; Liu J; Stevens CL; Foroozesh M
Drug Metab Lett; 2012; 6(4):275-84. PubMed ID: 23506553
[TBL] [Abstract][Full Text] [Related]
7. Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1.
Liu J; Taylor SF; Dupart PS; Arnold CL; Sridhar J; Jiang Q; Wang Y; Skripnikova EV; Zhao M; Foroozesh M
J Med Chem; 2013 May; 56(10):4082-92. PubMed ID: 23600958
[TBL] [Abstract][Full Text] [Related]
8. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.
Zhai S; Dai R; Friedman FK; Vestal RE
Drug Metab Dispos; 1998 Oct; 26(10):989-92. PubMed ID: 9763404
[TBL] [Abstract][Full Text] [Related]
9. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol.
Badawi AF; Cavalieri EL; Rogan EG
Metabolism; 2001 Sep; 50(9):1001-3. PubMed ID: 11555828
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
Takemura H; Itoh T; Yamamoto K; Sakakibara H; Shimoi K
Bioorg Med Chem; 2010 Sep; 18(17):6310-5. PubMed ID: 20696580
[TBL] [Abstract][Full Text] [Related]
11. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1.
Doostdar H; Burke MD; Mayer RT
Toxicology; 2000 Apr; 144(1-3):31-8. PubMed ID: 10781868
[TBL] [Abstract][Full Text] [Related]
12. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.
Shimada T; Yamazaki H; Foroozesh M; Hopkins NE; Alworth WL; Guengerich FP
Chem Res Toxicol; 1998 Sep; 11(9):1048-56. PubMed ID: 9760279
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.
Yamazaki H; Hatanaka N; Kizu R; Hayakawa K; Shimada N; Guengerich FP; Nakajima M; Yokoi T
Mutat Res; 2000 Dec; 472(1-2):129-38. PubMed ID: 11113705
[TBL] [Abstract][Full Text] [Related]
15. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
16. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxyl group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes.
Kim HJ; Lee SB; Park SK; Kim HM; Park YI; Dong MS
Arch Pharm Res; 2005 Oct; 28(10):1114-21. PubMed ID: 16276964
[TBL] [Abstract][Full Text] [Related]
18. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
19. Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition.
Shimada T; Kim D; Murayama N; Tanaka K; Takenaka S; Nagy LD; Folkman LM; Foroozesh MK; Komori M; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2013 Apr; 26(4):517-28. PubMed ID: 23432429
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
Masubuchi Y; Horie T
Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
